Michaela Luconi
Overview
Explore the profile of Michaela Luconi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
1923
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Catalano R, Nozza E, Altieri B, Esposito E, Croci G, Barbieri A, et al.
Cell Commun Signal
. 2025 Mar;
23(1):119.
PMID: 40038716
Background: The insulin-like growth factor 2 (IGF2) is overexpressed in 90% of adrenocortical carcinomas (ACC) and promotes cell proliferation via IGF1R and isoform A of insulin receptor (IRA). However, IGF2...
2.
Fei L, Propato A, Lotti G, Nardini P, Guasti D, Polvani S, et al.
Biomed Pharmacother
. 2025 Feb;
184:117900.
PMID: 39921946
Colorectal cancer (CRC) is the third most common cancer and the second cause of cancer death in the world. Emerging evidence suggests that the short-chain-fatty-acid butyrate diet-assumed or produced by...
3.
Cioppi F, Cantini G, Ercolino T, Chetta M, Zanatta L, Nesi G, et al.
Eur J Endocrinol
. 2024 Jun;
191(1):17-30.
PMID: 38917236
Objective: Adrenal cortical carcinoma (ACC) is a rare malignancy with a generally poor but heterogeneous prognosis, especially depending on the tumour stage at diagnosis. Identification of somatic gene alterations combined...
4.
Martinelli S, Cantini G, Propato A, Bani D, Guasti D, Nardini P, et al.
Sci Rep
. 2024 Apr;
14(1):8044.
PMID: 38580769
The crosstalk between the chromaffin and adrenocortical cells is essential for the endocrine activity of the adrenal glands. This interaction is also likely important for tumorigenesis and progression of adrenocortical...
5.
Canu L, Sparano C, Naletto L, De Filpo G, Cantini G, Rapizzi E, et al.
Front Endocrinol (Lausanne)
. 2024 Jan;
14:1320722.
PMID: 38269251
Purpose: Adrenocortical carcinoma (ACC) is a rare and aggressive tumor. ACC male patients under adjuvant mitotane therapy (AMT) frequently develop hypogonadism, however sexual function has never been assessed in this...
6.
Catalano R, Altieri B, Angelousi A, Arosio M, Bravi F, Canu L, et al.
Int J Mol Sci
. 2023 Dec;
24(23).
PMID: 38068896
The insulin-like growth factor 2 (IGF2) promotes cell growth by overactivating the IGF system in an autocrine loop in adrenocortical carcinomas (ACCs). The cytoskeleton protein filamin A (FLNA) acts as...
7.
Mannelli M, Bartoloni B, Cantini G, Nencioni E, Magherini F, Luconi M, et al.
Int J Mol Sci
. 2023 Nov;
24(22).
PMID: 38003534
Cachexia is a devastating pathology that worsens the quality of life and antineoplastic treatment outcomes of oncologic patients. Herein, we report that the secretome from murine colon carcinoma CT26 induces...
8.
Cantini G, Quartararo G, Ghezzi N, Goncalves D, Fei L, Propato A, et al.
Int J Obes (Lond)
. 2023 Nov;
48(2):247-253.
PMID: 37923928
Objective: Bariatric surgery not always results in satisfactory excess weight loss (EWL) in severe obesity. Given the economic and clinical costs of bariatric surgery failure, defining predictors of successful EWL...
9.
Cantini G, Niccolai E, Canu L, Di Gloria L, Baldi S, Propato A, et al.
Endocr Relat Cancer
. 2023 Sep;
30(10).
PMID: 37695690
The infiltrating microbiota represents a novel cellular component of the solid tumour microenvironment that can influence tumour progression and response to therapy. Adrenocortical carcinoma (ACC) is a rare and aggressive...
10.
Terzolo M, Fassnacht M, Perotti P, Libe R, Kastelan D, Lacroix A, et al.
Lancet Diabetes Endocrinol
. 2023 Aug;
11(10):720-730.
PMID: 37619579
Background: Adjuvant treatment with mitotane is commonly used after resection of adrenocortical carcinoma; however, treatment remains controversial, particularly if risk of recurrence is not high. We aimed to assess the...